Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT.
about
Molecular Imaging of Biomarkers in Breast CancerIntegrative analysis of cancer imaging readouts by networksAdvances in molecular imaging for breast cancer detection and characterizationRole of positron emission tomography for the monitoring of response to therapy in breast cancerInterstitial ultrasound ablation of vertebral and paraspinal tumours: parametric and patient-specific simulations.Correlation Between F-18 Fluorodeoxyglucose Positron Emission Tomography Metabolic Parameters and Dynamic Contrast-Enhanced MRI-Derived Perfusion Data in Patients with Invasive Ductal Breast Carcinoma.Assessment of stereotactic radiosurgery treatment response for brain metastases using MRI based diffusion index.Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).PET/CT and breast cancer.The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancerBone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abirateroneQuantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT.Causes and imaging features of false positives and false negatives on F-PET/CT in oncologic imagingAppearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.Systemic treatment in breast cancer: a primer for radiologistsFDG-PET/CT imaging biomarkers in head and neck squamous cell carcinomaQuantitative Evaluation of Therapeutic Response by FDG-PET-CT in Metastatic Breast CancerEffectiveness of 18F-FDG-PET/CT vs Bone Scintigraphy in Treatment Response Assessment of Bone Metastases in Breast Cancer.Longitudinal analysis of bone metabolism using SPECT/CT and (99m)Tc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis.VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT.Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary.Convergence technology in cancer medicine.MRI for response assessment in metastatic bone disease.Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence.Present and future role of FDG-PET/CT imaging in the management of breast cancer.Clinical PET-MR Imaging in Breast Cancer and Lung CancerEvaluation of radiographic and metabolic changes in bone metastases in response to systemic therapy with (18)FDG-PET/CT.Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.Accuracy of CT-based attenuation correction in PET/CT bone imaging.[Pharmacological therapy of urogenital cancer: rational routine diagnostic imaging].Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy.Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.Care of cancer patients with liver and bone metastases - the place of pharmaceutical care in a balanced plan, focused on the patient's needs and goals.
P2860
Q26772870-4117B62F-2306-4DE6-A389-972B3CED01F4Q26999069-D86464DF-F630-45C8-ACDE-38410D1A616CQ27000462-3C7A2A2F-0BBD-4FC5-BBB4-D9AB92FFCBD2Q28080621-ABE5CE5F-03F2-4EAF-ACFF-ABE0BD786952Q30395233-2E90E7F1-0B4A-4932-B444-D7F791A70B51Q30915309-2AD7C814-F027-4DC2-A346-00F65301D9DFQ33897079-3FE97AFC-654D-4008-AB29-B106BF056168Q34023973-8FF8AD9A-A1FA-408F-B8D9-C5B0A1530B01Q34213855-E1045F7C-99B5-4CFA-A9CB-42931021C618Q34256370-FACC44DD-2C5F-4E57-BD2D-71D4CE95CCAEQ34569318-9C11B3D7-8CE3-4142-93E4-9F709EFDF134Q34681161-210DDE93-21F2-4570-BF2C-1EDFBC9458E7Q35068005-CBDD3209-8B1A-4670-A142-FC4E07998E59Q35230789-BBD3EFEA-50CB-42F7-96AD-4F0CC06DA074Q35675742-26525248-ABD0-4E0C-A9B5-DB0FEB84FCDCQ36021686-0FBD6928-A997-4C6D-90C3-F555DC890EC7Q36510679-9D996AC0-E6F2-443E-AD15-D8E83C00626EQ36655475-474E5695-AEFD-44DB-8671-6BD37818618CQ36883389-D6A10DFE-8AFA-4153-B126-20BA5D938C50Q36992942-595ACB82-2F02-4150-B91C-632E1F0BB7B5Q37131629-5BEC5D2E-AAA2-463A-9C43-BE8D24EB228DQ37460998-8E544693-EFBC-4887-9D76-BDFBE480D124Q37477631-3E99B50C-36E6-46C3-826A-3A3DB6C3FC36Q37582345-4ECD291A-6E38-4A86-9649-B527DD973B23Q37716195-1065E45F-7366-435F-94D5-60F4F0936BB4Q37724181-9287421A-78D8-4B07-9F87-9CE270D88796Q37850452-0CD811A5-623D-45F2-A04C-61064E4C470DQ38086042-E87EF064-358A-4DF1-974A-3393B06E52F6Q38282521-D68425EE-C947-4BC8-A2BB-88FE7B4FD779Q38663416-59C17A7E-E8F7-450D-8ABD-9D4434C2F40EQ38687620-B3B0B188-7080-4619-83DD-36240896F666Q38945974-207B4CA7-C552-46B8-A13B-63E3C5EEB33FQ39328635-5EE88847-3405-45BE-A542-E1F0F88AC343Q40219495-9B4FD782-EB9B-47C1-A2FB-786885C07FF3Q42071725-7A30906C-23D2-4154-A6AF-C239EE45ECE9Q42172418-F85FAE59-0D4D-46F0-8060-D4894F7896C8Q44017338-DDB444E0-C79D-492B-97AA-42B60F13973EQ45823946-602D979F-28C3-45FD-A298-D4226DB58199Q46052641-C57EDB88-CCB8-45E5-86C5-B76C0C02C2D3Q47099005-27E30A8E-F061-4E47-AB19-BCA84CB54D71
P2860
Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bone metastases in patients wi ...... herapy with integrated PET/CT.
@en
Bone metastases in patients wi ...... herapy with integrated PET/CT.
@nl
type
label
Bone metastases in patients wi ...... herapy with integrated PET/CT.
@en
Bone metastases in patients wi ...... herapy with integrated PET/CT.
@nl
prefLabel
Bone metastases in patients wi ...... herapy with integrated PET/CT.
@en
Bone metastases in patients wi ...... herapy with integrated PET/CT.
@nl
P2093
P1433
P1476
Bone metastases in patients wi ...... herapy with integrated PET/CT.
@en
P2093
Cristina Gamez
Henry W D Yeung
Homer A Macapinlac
Massimo Cristofanilli
Shaheenah Dawood
Ukihide Tateishi
P304
P356
10.1148/RADIOL.2471070567
P407
P577
2008-04-01T00:00:00Z